Thioredoxin as a Molecular Target of Cyclopentenone Prostaglandins*

Takahiro Shibata {ddagger}, Takaaki Yamada {ddagger}, Takeshi Ishii {ddagger}, Shigenori Kumazawa §, Hajime Nakamura ¶, Hiroshi Masutani ¶, Junji Yodoi ¶ and Koji Uchida {ddagger} ||

From the {ddagger}Laboratory of Food and Biodynamics, Graduate School of Bioagricultural Sciences, Nagoya University, Nagoya 464-8601, Japan, §Department of Food and Nutritional Science, University of Shizuoka, Shizuoka 422-8529, Japan, and Department of Biological Responses, Institute for Virus Research, Kyoto University, Kyoto 606-8507, Japan

Received for publication, April 9, 2003 , and in revised form, April 21, 2003.


    ABSTRACT
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Prostaglandin (PG) D2, a major cyclooxygenase product in a variety of tissues and cells, readily undergoes dehydration to yield the bioactive cyclopentenone-type PGs of the J2 series, such as 15-deoxy-{Delta}12,14-PGJ2 (15d-PGJ2). We have shown previously that 15d-PGJ2 is a potent electrophile that causes intracellular oxidative stress and redox alteration in human neuroblastoma SH-SY5Y cells. In the present study, based on the observation that the electrophilic center of 15d-PGJ2 was involved in the pro-oxidant effect, we investigated the role of thioredoxin 1 (Trx), an endogenous redox regulator, against 15d-PGJ2-induced oxidative cell injury. It was observed that the 15d-PGJ2-induced oxidative stress was significantly suppressed by the Trx overexpression. In addition, the treatment of SH-SY5Y cells with biotinylated 15d-PGJ2 resulted in the formation of a 15d-PGJ2-Trx adduct, indicating that 15d-PGJ2 directly modified the endogenous Trx in the cells. To further examine the mechanism of the 15d-PGJ2 modification of Trx, human recombinant Trx treated with 15d-PGJ2 was analyzed by mass spectrometry. Matrix-assisted laser desorption ionization time-of-flight mass spectrometry analysis of the 15d-PGJ2-treated human recombinant Trx demonstrated the addition of one molecule of 15d-PGJ2 per protein molecule. Moreover, the electrospray ionization-liquid chromatography/mass spectrometry/mass spectrometry analysis identified two cysteine residues, Cys-35 and Cys-69, as the targets of 15d-PGJ2. These residues may represent the direct sensors of the electrophilic PGs that induce the intracellular redox alteration and neuronal cell death.


    INTRODUCTION
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
The prostaglandins (PGs)1 are a family of structurally related molecules that are produced by cells in response to a variety of extrinsic stimuli and regulate cellular growth, differentiation, and homeostasis (1, 2). PGs are derived from fatty acids, primarily arachidonate, which are released from membrane phospholipids by the action of phospholipases. Arachidonate is first converted to an unstable endoperoxide intermediate by cyclooxygenase and subsequently converted into one of several related products, including PGD2, PGE2, PGF2{alpha}, prostacyclin, and thromboxane A2, through the action of specific PG synthetases. Among them, PGD2 is a major cyclooxygenase product in a variety of tissues and cells and has marked effects on a number of biological processes, including platelet aggregation, relaxation of vascular and nonvascular smooth muscles, and nerve cell functions (3). It has been shown that PGD2 readily undergoes dehydration in vivo and in vitro to yield biologically active PGs of the J2 series, such as PGJ2, {Delta}12-PGJ2, and 15-deoxy-{Delta}12,14-PGJ2 (15d-PGJ2) (47). Members of the J2 series of the PGs, unlike other classes of eicosanoids, characterized by the presence of an electrophilic {alpha},{beta}-unsaturated carbonyl group in the cyclopentenone ring, have their own unique spectrum of biological effects, including inhibition of macrophage-derived cytokine production (8, 9) and I{kappa}B kinase (10, 11), induction of synoviocyte and endothelial cell apoptosis (12), induction of glutathione S-transferase gene expression (13) and intracellular oxidative stress (14), and potentiation of apoptosis in neuronal cells (15). Moreover, recent studies have shown that 15d-PGJ2 directly inhibits the NF-{kappa}B-dependent gene expression through covalent modification of critical cysteine residues in I{kappa}B kinase (10) and the DNA-binding domains of NF-{kappa}B subunits (11, 16).

Thioredoxin 1 (Trx) is a small and ubiquitously expressed protein originally identified in Escherichia coli and is evolutionarily conserved from prokaryotes to higher eukaryotes (1719). Human thioredoxin was cloned as an adult T cell leukemia-derived factor or interleukin-1-like factor (20, 21). Trx is an essential cofactor electron donor for ribonucleotide reductase but also has many other cellular functions, including regulation of transcription factors and apoptosis, and can act exogenously as a redox active growth factor (18, 22). In addition, Trx is known to play important roles in the redox regulation of signal transduction and in cytoprotection against oxidative stress (23, 24). The catalytic activity of Trx resides in its active site where the two redox-active cysteine residues (Cys-32 and Cys-35) undergo reversible oxidation/reduction. In addition to the conserved cysteine residues in the active site, three additional structural cysteine residues (Cys-62, Cys-69, and Cys-73) are present in the structure of the human Trx. The mechanisms for the reducing action of Trx is that substrate (X-S2) binds to a conserved hydrophobic surface and, in the hydrophobic environment of the complex, the thiolate of Cys-32, acting as a nucleophile, combines with the protein substrate to form a covalently linked mixed disulfide (-Cys-32-S-S-X). Finally, the deprotonated Cys-35 attacks the -Cys-32-S-S-X disulfide bond, releasing the reduced protein substrate and forming Trx-Cys-32-Cys-35-disulfide, which is then reduced by Trx reductase (25).

In our previous study, based on an extensive screening of diverse chemical agents on the induction of intracellular production of reactive oxygen species (ROS), we identified cyclopentenone PGs, such as 15d-PGJ2, as the potential inducers of intracellular oxidative stress in SH-SY5Y human neuroblastoma cells (14). As the intracellular events associated with the PG-induced oxidative stress, we observed (i) the cellular redox alteration represented by depletion of antioxidant defenses, such as glutathione and glutathione peroxidase, (ii) a transient decrease in the mitochondrial membrane potential ({Delta}{psi}), (iii) the production of protein-bound lipid peroxidation products, such as acrolein and 4-hydroxy-2-nonenal, and (iv) the accumulation of ubiquitinated proteins. In addition, the thiol compound, N-acetylcysteine, significantly inhibited the PG-induced ROS production, thereby preventing cytotoxicity. These observations suggested that the redox alteration was closely related to the pro-oxidant effect of the cyclopentenone PGs. In the present study, to investigate the correlation between the redox regulation and 15d-PGJ2-induced oxidative stress and to establish the cellular mechanism for protection against the endogenous electrophile, we investigated the role of Trx in 15d-PGJ2-induced oxidative cell injury.


    EXPERIMENTAL PROCEDURES
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Materials—15d-PGJ2 and 9,10-dihydro-15d-PGJ2 were obtained from Cayman Chemicals (Ann Arbor, MI). Horseradish peroxidase-linked anti-mouse IgG immunoglobulins and enhanced chemiluminescence (ECL) Western blotting detection reagents were obtained from Amersham Biosciences. The antibodies against p53 and ubiquitin were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA) and Biomeda Co. (Foster City, CA), respectively. The protein concentration was measured using the BCA protein assay reagent obtained from Pierce. UltraLink Immobilized NeutrAvidin Plus and 1-ethyl-3-(dimethylaminopropyl)carbodiimide were obtained from Pierce. The sequence grade modified trypsin was purchased from Promega. Human recombinant Trx (hrTrx) was produced by a previously described method (26) and kindly provided by Ajinomoto Co. Inc. (Kawasaki, Japan). 2',7'-Dichlorodihydrofluorescein diacetate (DCFH-DA) was from Molecular Probes, Inc. (Eugene, OR).

Cell Culture—SH-SY5Y cells were grown in Cosmedium-001 (CosmoBio, Tokyo, Japan) containing 5% Nakashibethu precolostrum newborn calf serum, 100 µg/ml penicillin, and 100 units/ml streptomycin. The cells were seeded in plates coated with poly-lysine and cultured at 37 °C. Cell viability was quantified by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as described previously (14).

Flow Cytometry Analysis of Intracellular ROS Production— DCFH-DA was used to measure the ROS (27, 28). Cells were incubated with 10 µM 2',7'-dichlorofluorescein diacetate (dissolved in Me2SO) for 30 min at 37 °C and then treated with different agents for an additional 30 min at 37 °C. After chilling on ice, the cells were washed with ice-cold PBS, scraped from the plate, and resuspended at 1 x 106 cells/ml in PBS containing 10 mM EDTA. The fluorescence was measured using a flow cytometer (Epics XL, Beckman Coulter).

Preparation of Biotinylated 15d-PGJ2The carboxyl group of 15d-PGJ2 was modified by amidation with EZ-link 5-(biotinamido)pentylamine by a modification of a previously described procedure (16). Biotinylated 15d-PGJ2 was purified through a reverse-phase HPLC eluted with a linear gradient of acetonitrile/water/acetic acid. The modified PG was then dried under argon and dissolved in Me2SO for further use.

Immunochemical Detection of Biotinylated 15d-PGJ2-binding Protein—Cells were fixed overnight in PBS containing 2% paraformaldehyde and 0.2% picric acid at 4 °C. The membranes were permeabilized by exposing the fixed cells to PBS containing 0.3% Triton X-100. The cells were then sequentially incubated in PBS solutions containing 2% bovine serum albumin and the primary anti-biotin antibody. The cells were then incubated for 1 h in the presence of fluorescein isothiocyanate-labeled goat anti-mouse IgG (Amersham Biosciences), rinsed with PBS containing 0.3% Triton X-100, and covered with anti-fade solution. Images of the cellular immunofluorescence were acquired using a confocal laser scanning microscope (Fluoroview; Olympus Optical Co., Ltd., Tokyo, Japan) with a x40 objective (488-nm excitation and 518-nm emission).

SDS-PAGE and Immunoblot Analysis—SDS-PAGE was performed according to Laemmli (29). A gel was transblotted onto a nitrocellulose membrane, incubated with Block Ace (40 mg/ml) for blocking, and washed with TBS containing 0.05% Tween 20 (TBS/Tween). This procedure was followed by the addition of HRP-conjugated NeutrAvidin or anti-mouse IgG antibody and ECL reagents (Amersham Biosciences). The bands were visualized by Cool Saver AE-6955 (ATTO, Tokyo, Japan).

Stable Transfection with Trx in SH-SY5Y Cells—SH-SY5Y cells were transfected with pcTrx-1 vector or with the vector alone using GenePORTERTM transfection reagent (Gene Therapy Systems, Inc.). In these experiments, 1 x 106 cells were incubated with DNA-GenePORTERTM mixture (2 µg of DNA/10 µl of GenePORTERTM) in 1 ml of serum-free Opti-MEM (Invitrogen) at 37 °C. After 6 h of incubation, 1 ml of complete medium was added, and cells were cultured for 18 h. Thereafter, stable transfectants were isolated by selection on 500 µg/ml G418 for ~3 weeks. Single clones of the stably transfected cells were isolated by limiting dilution. Several G418-resistant stable clones were maintained in medium containing 500 µg/ml G418.

Biotinylated 15d-PGJ2 Labeling of Trx in SH-SY5Y Cells—SH-SY5Y cells at 50% confluence were incubated with 50 µM biotinylated 15d-PGJ2 for 1 h. The cells were washed with PBS, harvested, and lysed in 10 mM Tris-HCl, pH 7.4, 1 mM EDTA, 0.1% SDS, 1% Triton, plus protease inhibitors. Cell lysates containing 200 µg of protein were incubated batch-wise with 50 µl of NeutrAvidin-Plus beads overnight at 4 °C with constant shaking. The beads were rinsed three times with lysis buffer by centrifugation at 6,000 rpm for 1 min. The proteins were eluted by boiling the beads in Laemmli sample buffer for 5 min and analyzed by SDS-PAGE followed by immunodetection with anti-Trx monoclonal antibody. In addition, the cell lysates were incubated with 3 µg of anti-Trx antibody overnight at 4 °C. The mixture was then treated with 50 µl of protein G-Sepharose (Amersham Biosciences) and incubated for 1 h at 4 °C. The mixture was then centrifuged (2,000 rpm, 5 min), rinsed three times with lysis buffer, and then boiled with the Laemmli sample buffer, and the biotinylated proteins were then subjected to immunoblot and detection with HRP-conjugated NeutrAvidin and ECL.

Enzyme-linked Immunosorbent Assay (ELISA)—To coat the wells of the microtiter plate, 100 µl/well hrTrx (0.1 mg/ml) in PBS was used and then incubated overnight at 4 °C. Following washing with TBS/Tween, 100 µl of the biotinylated 15d-PGJ2 solution was added to the wells. After incubation for 2 h at 37 °C followed by washing with TBS/Tween, each well was filled with 200 µl of Block Ace solution (4 mg/ml) for 1 h at 37 °C. The HRP-conjugated NeutrAvidin was then added to the wells at 100 µl/well for 1 h at 37 °C. After washing, 100 µl of 0.05 M citrate buffer, pH 5.0, containing 0.4 mg/ml o-phenylenediamine and 0.003% H2O2 was added and incubated for several minutes at room temperature in the dark. The reaction was terminated by the addition of 2 M sulfuric acid, and the absorbance at 492 nm was read on a micro-ELISA plate reader.

Titration of Trx Sulfhydryls with DTNB—The reactivity of the sulfhydryl groups in hrTrx was determined by titration with DTNB by the method of Ellman (30), as modified by Riddles et al. (31). A 0.1 mg/ml hrTrx sample was treated with 0.1 mM 15d-PGJ2, and after dialysis against PBS, the protein was denatured with 8 M guanidine hydrochloride containing 13 mM EDTA and 133 mM Tris, pH 8, and reacted with DTNB (1 mM) at room temperature for 5 min. The reaction was monitored as an increase in absorbance at 412 nm. The concentration of sulfhydryl groups was calculated using a standard curve with N-acetylcysteine.

Matrix-assisted Laser Desorption Ionization Time-of-flight Mass Spectrometry (MALDI-TOF MS)—The native and 15d-PGJ2-modified hrTrx were mixed with a saturated solution of 3,5-dimethoxy-4-hydroxycinnamic acid (Sigma) containing 75% acetonitrile and 0.1% trifluoroacetic acid and dried on stainless steel targets at room temperature and pressure. The trypsin-digested hrTrx were mixed with a saturated solution of {alpha}-cyano-4-hydroxycinnamic acid (Sigma) containing 50% acetonitrile and 0.1% trifluoroacetic acid and dried on stainless steel targets at room temperature and pressure. The analyses were performed using an Autoflex matrix-assisted laser desorption ionization time-of-flight mass spectrometer (Bruker, Bremen, Germany) with a nitrogen laser (337 nm). All analyses were in the positive ion mode, and the instrument was calibrated immediately prior to each series of studies.

Electrospray Ionization-Liquid Chromatography/Mass Spectrometry/Mass Spectrometry (ESI-LC/MS/MS) Analysis—The ESI-LC/MS (and ESI-LC/MS/MS) analyses were performed on an LCQ ion trap mass system (ThermoQuest) equipped with an electrospray ion source. The electrospray system employed a 5-kV spray voltage and a capillary temperature of 260 °C.

Peptide Mapping—The native and 15d-PGJ2-modified hrTrx (1 mg/ml) were digested with modified trypsin in 0.25 ml of 50 mM Tris-HCl buffer, pH 8.8, at 37 °C for 24 h using an enzyme:substrate ratio of 1:100 (w/w). Peptide samples were analyzed by a reversed-phase HPLC, a system that consisted of a nanospace SI-1 HPLC system (SHISEIDO Co., Ltd., Tokyo, Japan) with a FP-1520 fluorescence detector (Jasco Co., Tokyo, Japan), using a Capcell Pak C18 UG120 column (2.0 x 250-mm inner diameter; SHISEIDO Co., Ltd., Tokyo, Japan). These samples were eluted with a linear gradient of water containing 0.1% formic acid (Solvent A) and acetonitrile containing 0.08% formic acid (Solvent B) (time = 0–3 min, 10% B; 3–45 min, 10–40% B; 45–50 min, 40–50% B; 50–52 min, 50–80% B). The flow rate was 0.2 ml/min, and the column temperature was controlled at 40 °C. The chromatograms were recorded at 215 nm.


    RESULTS
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Pro-oxidant and Cytotoxic Effects of 15d-PGJ2 Can Be Attributed to Its Electrophilic Center—It has been suggested that the {alpha},{beta}-unsaturated carbonyl group in the cyclopentenone ring of 15d-PGJ2 is a prerequisite for the induction of intracellular oxidative stress and cytotoxicity (14). To prove this hypothesis, human neuroblastoma SH-SY5Y cells were exposed to 15d-PGJ2 and its analog 9,10-dihydro-15d-PGJ2 (Fig. 1A), and induction of ROS production and cytotoxicity were examined. As shown in Fig. 1B, the intracellular ROS production in SH-SY5Y cells was induced by 15d-PGJ2 in a dose-dependent manner. The level of ROS in the cells exposed to 15d-PGJ2 (50 µM) was ~30-fold higher than that of the control. In contrast to this potent pro-oxidant effect of 15d-PGJ2, 9,10-dihydro-15d-PGJ2 had no significant effects on the ROS production. In a manner similar to the induction of the ROS production, 15d-PGJ2 (20 µM) resulted in a rapid decrease in the MTT reduction levels to 10% of the basal levels after 24 h of exposure, whereas the MTT reduction levels were maintained at about basal level in the cells exposed to 9,10-dihydro-15d-PGJ2 (Fig. 1C). Thus, the reduction of the double bond in the cyclopentenone ring of 15d-PGJ2 virtually abolished the pro-oxidant and cytotoxic effects of 15d-PGJ2, indicating that these biological activities can be attributed to the electrophilic center of 15d-PGJ2. Although proliferative effects of cyclopentenone-type PGs have been described in several cell types when used at nanomolar or low micromolar concentrations (3234), we did not see such effect in human neuroblastoma SH-SY5Y cells (Fig. 1C).



View larger version (18K):
[in this window]
[in a new window]
 
FIG. 1.
Pro-oxidant and cytotoxic effects of 15d-PGJ2 and its analog. A, chemical structures of 15d-PGJ2 (left) and 9,10-dihydro-15d-PGJ2 (right). Asterisk depicts electrophilic carbon (position 9). B, intracellular ROS production induced by 15d-PGJ2 (open bar) and 9,10-dihydro-15d-PGJ2 (closed bar) in SH-SY5Y cells. SH-SY5Y cells were incubated with DCFH-DA (10 µM) for 30 min and then treated with 15d-PGJ2 or 9,10-dihydro-15d-PGJ2 for 1 h. The fluorescence intensity of more than 10,000 cells was analyzed using a flow cytometer. Data are expressed as percent of control culture conditions. Results show the mean ± S.D. of three experiments. *, p < 0.05. C, viability of 15d-PGJ2-treated (open bar) and 9,10-dihydro-15d-PGJ2-treated (closed bar) SH-SY5Y cells. Cells were exposed to each concentration of 15d-PGJ2 or 9,10-dihydro-15d-PGJ2 for 24 h. The cell viability was measured by the MTT assay. Data are expressed as a percent of control culture conditions. Results show the mean ± S.D. of three experiments. *, p < 0.05; ***, p < 0.005.

 

Effect of Trx Overexpression on 15d-PGJ2-induced Oxidative Stress—The fact that cyclopentenone PGs are susceptible to nucleophilic addition reactions with thiols suggests that the action of the cyclopentenone PGs are closely related to the direct reaction with glutathione and/or other thiol compounds. However, L-buthionine-S,R-sulfoximine, a specific inhibitor of glutathione biosynthesis, itself, did not so effectively induce intracellular ROS production and cell death, indicating that the effects of the cyclopentenone PGs may not merely result from glutathione depletion alone (14). This and the finding that the electrophilic center of 15d-PGJ2 is involved in the prooxidant effect (Fig. 1) suggested that other cellular redox molecules might play crucial roles in protection against 15d-PGJ2-induced oxidative cell injury. Based on the previous findings that Trx, a key molecule in the maintenance of cellular redox balance, plays critical roles in protecting against oxidative stress and mediating signal transduction (35), we investigated the role of this redox regulator on the 15d-PGJ2-induced ROS production. To this end, we established the Trx-overexpressing derivatives of SH-SY5Y cells by stable transfection with Trx cDNA. The Trx expression vector (pcTrx-1) was introduced into the SH-SY5Y cells with the selectable pcDNA, and four clones with resistance to G418 were selected. As a control, SH-SY5Y cells transfected with a control vector were similarly selected for G418 resistance. Four clones were isolated. As shown in Fig. 2A, the Trx-transfected clones Trx-1 and Trx-3 demonstrated a readily detectable expression of the Trx protein by immunoblot analysis with the anti-Trx monoclonal antibody, whereas the control transfected cells Neo-1, -2, -3, and -4 did not.



View larger version (26K):
[in this window]
[in a new window]
 
FIG. 2.
Trx overexpression suppresses 15d-PGJ2-induced intracellular oxidative stress and cell death. A, immunoblot analysis of expression of Trx protein levels in established Trx-overexpressing derivatives of SH-SY5Y cells (lanes 5–8) and vector control cells (lanes 1–4). B, intracellular ROS production induced by 15d-PGJ2. Control vector (open bar) and Trx-overexpressed (closed bar) SH-SY5Y cells were incubated with DCFH-DA (10 µM) for 30 min and then treated with 15d-PGJ2 for 1 h. The fluorescence intensity of more than 10,000 cells was analyzed using a flow cytometer. Data are expressed as percent of control culture conditions. Results show the mean ± S.D. of three experiments. *, p < 0.05. C, viability of control vector (open bar) and Trx-overexpressed (closed bar) SH-SY5Y cells exposed to 15d-PGJ2. Cells were exposed to each concentration of 15d-PGJ2 for 24 h. The cell viability was measured by the MTT assay. Data are expressed as a percent of control culture conditions. Results show the mean ± S.D. of three experiments. **, p < 0.01.

 

For the experiments shown below, the results were compared between Neo-2 and Trx-3, to assess the effectiveness of expressed Trx in protection against 15d-PGJ2-induced cell injury. First, we measured the intracellular ROS production by flow cytometry analysis. As shown in Fig. 2B, the ROS production in the control SH-SY5Y was significantly induced by 15d-PGJ2. The level of ROS in the cells exposed to 15d-PGJ2 (50 µM) was about 5-fold higher than that of the vehicle-treated cells, whereas the intracellular ROS production in the Trx-overexpressed cells exposed to 15d-PGJ2 was inhibited about 40% of the vector control. Next, we examined the effect of Trx on the 15d-PGJ2-induced cytotoxicity. The transfected SH-SY5Y cells were examined by MTT assay for sensitivity to cytotoxicity induced by continuous exposure (24 h) to 15d-PGJ2. As shown in Fig. 2C, 15d-PGJ2 (5 or 10 µM) resulted in a decrease in the MTT reduction levels to 10% of the basal levels on vector control cells within 24 h of exposure, whereas the Trx-overexpressing cells were more resistant to 15d-PGJ2-induced cell death than the control cells. We also examined the effect of Trx overexpression on the accumulation of ubiquitinated proteins and p53, both of which have been suggested to be involved in the 15d-PGJ2-induced cell death (14, 15), and found that Trx could have significantly inhibited the accumulation of these proteins (data not shown). These data strongly suggest that Trx may be involved, at least in part, in the protection against the 15d-PGJ2 cytotoxicity.

Covalent Binding of 15d-PGJ2 to Endogenous Trx in SH-SY5Y Cells—Because Trx contains reactive sulfhydryl groups, it can be hypothesized that Trx may directly react with 15d-PGJ2. Apart from low molecular weight 15d-PGJ2-glutathione adduct, the 15d-PGJ2-thiol conjugates are associated with high molecular weight proteins. The list of 15d-PGJ2-modified proteins so far includes I{kappa}B kinase (10), Trx reductase (36), and keap1.2 Accordingly, we studied the direct interaction between 15d-PGJ2 and endogenous Trx in SH-SY5Y cells. To determine whether 15d-PGJ2 reacts with Trx or other proteins, we prepared a biotinylated 15d-PGJ2 (Fig. 3A), which retains the {alpha},{beta}-unsaturated ketone substituent and the electrophilic {beta}-carbon of 15d-PGJ2. As shown in Fig. 3B, incorporation of the biotinylated 15d-PGJ2 into the cells was observed in SH-SY5Y cells by immunocytochemical detection, suggesting the utility of the biotinylated 15d-PGJ2. We then attempted to detect the 15d-PGJ2-Trx adduct in the cells exposed to the biotinylated 15d-PGJ2. To this end, the SH-SY5Y cells were treated with 50 µM biotinylated 15d-PGJ2 for 1 h, and the cell lysate was incubated with NeutrAvidin beads. After washing with lysis buffer, proteins bound to the resin through biotinylated 15d-PGJ2 were eluted with SDS-PAGE sample buffer, and Trx was detected by immunoblot analysis with the anti-Trx monoclonal antibody (Fig. 3C). Alternatively, cell lysates were subjected to immunoprecipitation with an anti-Trx monoclonal antibody, and the presence of biotinylated 15d-PGJ2-modified proteins was detected by immunoblot analysis with HRP-conjugated NeutrAvidin (Fig. 3C). Thus, it appeared that 15d-PGJ2 reacted to an appreciable extent with endogenous Trx, itself, in intact SH-SY5Y cells.



View larger version (35K):
[in this window]
[in a new window]
 
FIG. 3.
Cellular accumulation of biotinylated 15d-PGJ2 in SH-SY5Y cells. A, chemical structure of biotinylated 15d-PGJ2. B, immunocytochemical detection of biotinylated 15d-PGJ2 in SH-SY5Y cells. The cells were incubated with 10 µM biotinylated 15d-PGJ2 at 37 °C. Fluorescein isothiocyanate fluorescence (biotinylated 15d-PGJ2; green) is shown in the left column of panels a–c, propidium iodide (nuclear; red) is shown in the center column of panels d–f, and the corresponding merged (superimposed) images are shown in the right column of panels g–i (yellow represents colocalization). C, interaction between Trx and 15d-PGJ2 in intact SH-SY5Y cells. Exponentially growing SH-SY5Y cells were treated with biotinylated 15d-PGJ2 for 1 h. Cell lysates were incubated with immobilized NeutrAvidin or with anti-Trx-Sepharose, as indicated. The presence of Trx was detected by immunoblot analysis, and the incorporation of biotinylated 15d-PGJ2 into Trx immunoprecipitates was detected with HRP-NeutrAvidin and ECL.

 

Covalent Binding of 15d-PGJ2 to Human Recombinant Trx— Covalent binding of 15d-PGJ2 to Trx also occurred upon in vitro incubation of hrTrx with biotinylated 15d-PGJ2. As shown in Fig. 4A, the biotinylated 15d-PGJ2 was bound to hrTrx in a dose-dependent manner. In addition, binding of the biotinylated 15d-PGJ2 to hrTrx was also shown by ELISA analysis (Fig. 4B). Moreover, free sulfhydryl groups within the 15d-PGJ2-treated hrTrx were titrated with DTNB. As shown in Fig. 4C, the exposure of hrTrx to 15d-PGJ2 resulted in the loss of cysteine residues, and approximately two cysteine residues per hrTrx were lost after 1 h; however, 9,10-dihydro-15d-PGJ2 did not. These data suggest that 15d-PGJ2 modifies the free sulfhydryl groups within the hrTrx molecules.



View larger version (20K):
[in this window]
[in a new window]
 
FIG. 4.
Covalent modification of human recombinant Trx by 15d-PGJ2. A, immunoblot analysis of hrTrx treated with biotinylated 15d-PGJ2. B, ELISA analysis of hrTrx treated with biotinylated 15d-PGJ2. Trapping ELSIA analysis was performed as described under "Experimental Procedures." In A and B, hrTrx (0.1 mg/ml) was incubated with 0.1 mM biotinylated 15d-PGJ2 in PBS at 37 °C. C, loss of sulfhydryl contents in hrTrx upon incubation with 15d-PGJ2 or 9,10-dihydro-15d-PGJ2. hrTrx (0.1 mg/ml) was incubated with 0.1 mM 15d-PGJ2 or 0.1 mM 9,10-dihydro-15d-PGJ2 in PBS at 37 °C.

 

MALDI-TOF MS Analysis of 15d-PGJ2-treated hrTrx—To further elucidate the mechanism for modification of Trx by 15d-PGJ2, we attempted to identify the modification sites of the protein by monitoring the formation of the 15d-PGJ2 Michael adducts by mass spectrometric methods. As shown in Fig. 5, the MALDI-TOF MS analysis of the native hrTrx revealed a peak of m/z 11,785. When hrTrx was incubated with 0.1 mM 15d-PGJ2 in 50 mM sodium phosphate buffer, pH 7.4, for 2 h at 37 °C, some unmodified hrTrx subunits were observed, as was the peak (m/z 12,099) corresponding to the addition of one molecule of 15d-PGJ2 per protein. Further incubations resulted in the appearance of peaks corresponding to the addition of one to two molecules of 15d-PGJ2 (data not shown).



View larger version (17K):
[in this window]
[in a new window]
 
FIG. 5.
MALDI-TOF MS analysis of 15d-PGJ2-treated hrTrx. hrTrx (0.1 mg/ml) was incubated with 0.1 mM 15d-PGJ2 in PBS for 30 min at 37 °C.

 

Identification of the 15d-PGJ2 Modification Site in hrTrx—To confirm the 15d-PGJ2 modification sites, the native and 15d-PGJ2-treated hrTrx were digested with trypsin and then analyzed by ESI-LC/MS. Peptide mass mapping by ESI-LC/MS analysis of the tryptic peptides from the native hrTrx provided identification of the peptides accounting for 92% of the protein sequence (see Fig. 6A and Table I). Relative to the calculated mass of the unmodified peptide, which showed an increased mass of +316 Da corresponding to the addition of a single molecule of 15d-PGJ2, namely Tp-1 and Tp-2, were detected by ESI-LC/MS analysis (Fig. 6A). Moreover, these two peptides were also detected in the MALDI-TOF MS analysis of tryptic peptides from the 15d-PGJ2-treated hrTrx (see Fig. 6B and Table I).



View larger version (22K):
[in this window]
[in a new window]
 
FIG. 6.
Mass spectrometry analysis of peptides from hrTrx digested with trypsin. A, native hrTrx (bottom) and 15d-PGJ2-treated hrTrx (top) were digested with trypsin, and ESI-LC/MS was performed with an LCQ ion trap mass spectrometer as described under "Experimental Procedures." The elution positions of the identified tryptic peptides are indicated in the total ion current and summarized in Table I. B, MALDI-TOF MS analysis of peptide from hrTrx digested with trypsin.

 

View this table:
[in this window]
[in a new window]
 
TABLE I
Peptides identified by ESI-LC/MS and MALDI-TOF MS from hrTrx

 

To identify the 15d-PGJ2-modification site, the 15d-PGJ2-modified peptides, Tp-1 and Tp-2, were further analyzed by ESI-LC/MS/MS without additional chromatography. The MS/MS spectrum of the [M + H]+ at m/z 1,940.7 from the 15d-PGJ2-modified peptide (Tp-1; LVVVDFSATWCGPCK) is shown in Fig. 7. In the MS/MS analysis, the singly charged N-terminal product ions (b8 and b11) and its H2O loss ions (b6–18, b9–18, b10–18, and b12–18) were observed. The C-terminal fragment ions (y4, y5, y6, y7, y8, y9, y10, y11, y12, and y13), N-terminal product ion (b14), and the H2O loss fragment ion (y3–18) were observed to increase 316 Da, suggesting that the 15d-PGJ2 modification site is in the sequence on Cys-35 but not Cys-32. The MS/MS spectrum of the [M + 2H]2+ at m/z 1,518.9 from the 15d-PGJ2-modified peptide (Tp-2; YSNVIFLEVDVDDCQDVASECEVK) is shown in Fig. 8. In the MS/MS analysis, the singly charged N-terminal product ions (b7, b8, b9, b11, b12, b13, b15, b16, and b17) and its H2O loss fragment ions (b6–18, b7–18, b8–18, b9–18, b11–18, b14–18, b15–18, b16–18, and b17–18) and doubly charged N-terminal product ions (b202+ and b212+) were observed. The singly charged C-terminal product ions (y4, y5, y6, y8, y9, y11, y12, y13, y14, and y15) and doubly charged product ions (y182+, y192+, and b232+) were observed to increase 316 Da. These data suggest that the 15d-PGJ2 modification is associated with Cys-69 on the peptide Tp-2. On the other hand, the modification of the other cysteine residues, Cys-62 and Cys-73, were not detected (data not shown). Thus, we identified the two target cysteine residues, Cys-35 and Cys-69, of the 15d-PGJ2 modification in Trx.



View larger version (29K):
[in this window]
[in a new window]
 
FIG. 7.
ESI-LC/MS/MS spectrum of the [M + H]+ at m/z 1940.7 from the 15d-PGJ2-modified peptide (Tp-1) with the sequence LVVVDFSATWCGPCK.

 


View larger version (38K):
[in this window]
[in a new window]
 
FIG. 8.
ESI-LC/MS/MS spectrum of the [M + 2H]2+ at m/z 1518.9 from the 15d-PGJ2-modified peptide (Tp-2) with the sequence YSNVIFLEVDVDDCQDVASECEVK.

 


    DISCUSSION
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
PGs are physiologically present in body fluids in picomolar to nanomolar concentrations (37); however, the arachidonate metabolism is significantly increased in several pathological conditions, including hyperthermia, infection, and inflammation (38), and local PG concentrations in the micromolar range have been detected at sites of acute inflammation (39). In addition, elevated cyclopentenone PG synthesis has also been detected in the late phases of inflammation (40). Therefore, the up-regulation of PG biosynthesis is suggested to be involved in the pathophysiological processes relevant to inflammatory responses. The findings that (i) PGD2, the precursor of cyclopentenone PGs, is one of the most abundantly produced PGs in several tissues; (ii) PGD2 can be readily converted to J2 PGs in the presence of plasma in vitro (5); and (iii) the cyclopentenone PGs, such as 15d-PGJ2, shown to be formed from PGD2 in vivo (6), strongly suggest that the levels of the PGD2 derivatives may reach functionally significant levels during inflammation and its related disorders. The involvement of PGs in neurodegenerative disorders is supported by clinical and epidemiological studies. For example, nonsteroidal anti-inflammatory drugs, which inhibit PG synthesis, reduce the deterioration rate of the cognitive behavior in Alzheimer's disease patients (4146). In addition, rheumatoid arthritis patients who are on high doses of anti-inflammatory drugs have a reduced incidence of this disease (4750). We have shown recently (15) that 15d-PGJ2 is indeed accumulated in the spinal cord of sporadic amyotrophic lateral sclerosis patients, mainly occurring in the motor neurons of the anterior horn. Therefore, it is likely that cyclooxygenase-2 up-regulation, through its pivotal role in inflammation, followed by the enhanced intracellular production of cyclopentenone PGs, is involved in neurodegenerative processes.

In our previous study (14), as part of an effort to identify the endogenous inducer of intracellular oxidative stress and to elucidate the molecular mechanism underlying the oxidative stress-mediated cell degeneration, we examined the oxidized fatty acid metabolites for their ability to induce intracellular ROS production in SH-SY5Y cell in vitro and found that the J2 series of the PGs represents the most potent inducers. This and the observations that the intracellular ROS production was accompanied by the alteration of the cellular redox status and the production of lipid peroxidation-derived highly cytotoxic aldehydes, such as acrolein and 4-hydroxy-2-nonenal, which could also induced the intracellular ROS production, suggested that intracellular oxidative stress constitutes a pivotal step in the pathway of cellular dysfunction induced by the PGs. In the present study, to further establish the molecular mechanism underlying the PG-induced cell injury, we examined the effect of 9,10-dihydro-15d-PGJ2, an analog of 15d-PGJ2, on the induction of ROS production and cell damage and found that the reduction of the double bond in the cyclopentenone ring of 15d-PGJ2 virtually abolished the pro-oxidant and cytotoxic effects of 15d-PGJ2 (Fig. 1). Thus, the pro-oxidant action of 15d-PGJ2 appeared to operate via mechanisms that depend upon the reactivity of its electrophilic {alpha},{beta}-unsaturated ketones.

The reactive center of the cyclopentenone PGs has been proposed to account for some of their receptor-independent biological actions (10, 51). They can covalently react by means of the Michael addition reaction with nucleophiles, such as the free sulfhydryls of glutathione and cysteine residues in cellular proteins that play an important role in the control of the redox cell-signaling pathways (10, 51, 52). This, in turn, suggested that cellular redox molecules might play crucial roles in the regulation of the biological functions of cyclopentenone PGs. In the present study, we investigated the role of Trx on the 15d-PGJ2-induced oxidative cell damage. Trx, a key molecule in the maintenance of the cellular redox balance, has been shown to play critical roles in protecting against oxidative stress and mediating signal transduction (53). Indeed, the overexpression of cytoplasmic Trx protected against oxidative stress-induced cell death (35, 54). Andoh et al. (55) have also shown that, using serum deprivation and 1-methyl-4-phenylpyridium as models, Trx prevents the oxidative stress-induced apoptosis of SH-SY5Y cells. Consistent with these results, Trx conferred protection on SH-SY5Y cells against 15d-PGJ2-induced cell damage (Fig. 2).

It was proposed that the protection of oxidative cell damage by Trx might be achieved through a direct electrophile scavenger function. To prove this hypothesis, using a biotinylated 15d-PGJ2, we explored the incorporation of 15d-PGJ2 into cellular proteins (Fig. 3B) and cellular Trx (Fig. 3C). Our results show that biotinylated 15d-PGJ2 modifies Trx when added to intact cells. These results raise the possibility that Trx plays an important role in the protection against the pro-oxidant effects of the electrophilic PG, at least at the pharmacological doses employed in most biochemical studies. Several previous observations have indicated that PGD2 and its J-ring metabolites might exert effects through interactions with intracellular proteins. Narumiya et al. (56) have shown that radiolabeled {Delta}12-PGJ2 is actively incorporated into cells and transferred to the nucleus, where it is associated with proteins. Some PGs, including PGD2, PGJ2, and {Delta}12-PGJ2, have been shown to bind with high affinity to the liver fatty acid-binding protein and intracellular protein involved in the uptake, intracellular transport, and metabolism of free fatty acids and their acyl-CoA esters (57). 15d-PGJ2 has been shown to directly inhibit NF-{kappa}B activation either by blocking I{kappa}B kinase activity through covalent modifications of critical cysteine residues in I{kappa}B kinase {beta} or by interacting with cysteine residues in the DNA-binding domain of the NF-{kappa}B subunit p65 (10, 58). Moreover, the NF-{kappa}B p50 subunit was also identified to be a target for covalent modification by 15d-PGJ2 leading to the inhibition of DNA binding (16). Moos et al. (36) have also reported the covalent modification and inhibition of Trx reductase by cyclopentenone PGs. More recently, Olivia et al. (59) have shown that 15d-PGJ2 induces H-Ras activation mediated by direct interaction of 15d-PGJ2 to the cysteine residue (Cys-184) of H-Ras. This and our observations suggest cyclopentenone PGs could induce redox alteration due, at least in part, to the inhibition of the Trx-dependent regulatory systems.

The covalent binding of 15d-PGJ2 to Trx was examined upon in vitro incubation of hrTrx with biotinylated 15d-PGJ2. The observations (Fig. 4) that the biotinylated 15d-PGJ2 was significantly incorporated into hrTrx and that the exposure of hrTrx to the biotinylated 15d-PGJ2 resulted in the loss of cysteine residues confirms that 15d-PGJ2 is a chemically reactive species capable of alkylating nucleophilic sites in the protein Trx under physiological conditions. In this study, we have used a combination of MALDI-TOF MS and ESI-LC/MS (ESI-LC/MS/MS) to elucidate the mechanism for modification of Trx by 15d-PGJ2. The MADL-TOF MS analysis of 15d-PGJ2-treated hrTrx showed that the reaction of Trx with 15d-PGJ2 resulted in the formation of at least two adducts, the major of which is a monoadduct (Fig. 5). The 15d-PGJ2-Trx adduct was further digested with trypsin, and the peptides (Tp-1 and Tp-2), containing the 15d-PGJ2-cysteine adduct, were sequenced by ESI-LC/MS/MS. Among two catalytic site cysteine residues (Cys-32 and Cys-35) and three other cysteine residues (Cys-62, Cys-69, and Cys-73) in human Trx, the sequencing analysis showed the site of modification to be exclusively at Cys-35 and Cys-69 (Figs. 6, 7, 8). These data suggest that 15d-PGJ2 may not be randomly incorporated into free SH groups but instead may alkylate cysteine groups in specific environments. The preference for alkylation of Cys-35 to Cys-32 was unexpected, because (i) the active site of Trx is known to have the cysteines on a protruding loop with Cys-32 more exposed than Cys-35 (60), and (ii) Cys-32 has a lower pKa than Cys-35 (61). Indeed, Erve et al. (62) showed that S-(2-chloroethyl)glutathione exclusively alkylates Cys-32 with no alkylation at Cys-35. Although the detailed mechanism for this preferential alkylation of Cys-35 by 15d-PGJ2 remains unclear, the modification of one of the two active site cysteines may be directly associated with the abolishment of its redox regulatory functions, because Cys-35 is critical to releasing the reduced protein substrate followed by the formation of a disulfide linkage with Cys-32. On the other hand, the non-catalytic cysteine residues have also been reported to undergo covalent modification. Haendeler et al. (63) showed recently that Trx is S-nitrosylated on Cys-69, which is located between an acidic and a basic amino acid in the proposed consensus motif for S-nitrosylation (64, 65). It has been suggested that S-nitrosylation on Cys-69 is involved in an anti-apoptotic mechanism of Trx that differs from the anti-apoptotic mechanisms mediated by the binding of proapoptotive proteins to Cys-32 and Cys-35 (63). Because this S-nitrosylation is required for scavenging ROS and for preserving the redox regulatory activity of Trx, the 15d-PGJ2 modification of Cys-69 may result in an increase in the formation of ROS. This may be associated with our previous finding (14) that 15d-PGJ2 and other cyclopentenone-type PGs can potently induce intracellular oxidative stress in SH-SY5Y human neuroblastoma cells.

In summary, our results identified the Trx as a molecular target for the covalent modification by 15d-PGJ2, providing a biochemical basis for the redox alteration by cyclopentenone PG. In addition, we identified the two target cysteine residues, Cys-35 and Cys-69, of the 15d-PGJ2 modification within Trx. The Trx modification by 15d-PGJ2 may be one of the mechanisms by which 15d-PGJ2 induces intracellular oxidative stress and neuronal cell death.


    FOOTNOTES
 
* This work was supported in part by a research grant from the Ministry of Education, Culture, Sports, Science, and Technology, by the Center of Excellence Program in the 21st Century in Japan, and by research fellowships from the Japan Society for the Promotion of Science (to T. S.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

|| To whom correspondence should be addressed: Laboratory of Food and Biodynamics, Graduate School of Bioagricultural Sciences, Nagoya University, Nagoya 464-8601, Japan. Fax: 81-52-789-5741. E-mail: uchidak{at}agr.nagoya-u.ac.jp

1 The abbreviations used are: PG(s), prostaglandin(s); 15d-PGJ2, 15-deoxy-{Delta}12,14-PGJ2; Trx, thioredoxin; ELISA, enzyme-linked immunosorbent assay; ROS, reactive oxygen species; DCFH-DA, 2',7'-dichlorodihydrofluorescein diacetate; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; HRP, horseradish peroxidase; PBS, phosphate-buffered saline; DTNB, 5,5'-dithiobis(2-nitrobenzoic acid); hrTrx, human recombinant Trx; ECL, enhanced chemiluminescence; HPLC, high performance liquid chromatography; TBS, Tris-buffered saline; MALDI-TOF, matrix-assisted laser desorption ionization time-of-flight; MS, mass spectrometry; ESI-LC, electrospray ionization-liquid chromatography. Back

2 K. Itoh, M. Mochizuki, Y. Ishii, T. Shibata, Y. Kawamoto, T. Ishii, V. Kelly, K. Sekizawa, K. Uchida, and M. Yamamoto, submitted for publication. Back


    ACKNOWLEDGMENTS
 
We thank Dr. Takeshi Kumagai (Nagoya University) for helpful advice.



    REFERENCES
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Smith, W. L. (1989) Biochem. J. 259, 315-324[Medline] [Order article via Infotrieve]
  2. Smith, W. L. (1992) Am. J. Physiol. 263, F181-F191[Medline] [Order article via Infotrieve]
  3. Giles, H., and Leff, P. (1988) Prostaglandins 35, 277-300[CrossRef][Medline] [Order article via Infotrieve]
  4. Fitzpatrick, F. A., and Wynalda, M. A. (1983) J. Biol. Chem. 258, 11713-11718[Abstract/Free Full Text]
  5. Kikawa, Y., Narumiya, S., Fukushima, M., Wakatsuka, H., and Hayaishi, O. (1984) Proc. Natl. Acad. U. S. A. 81, 1317-1321[Abstract]
  6. Hirata, Y., Hayashi, H., Ito, S., Kikawa, Y., Ishibashi, M., Sudo, M., Miyazaki, H., Fukushima, M., Narumiya, S., and Hayashi, O. (1988) J. Biol. Chem. 263, 16619-16625[Abstract/Free Full Text]
  7. Shibata, T., Kondo, M., Osawa, T., Shibata, N., Kobayashi, M., and Uchida, K. (2002) J. Biol. Chem. 277, 10459-10466[Abstract/Free Full Text]
  8. Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., and Glass, C. K. (1998) Nature 391, 79-82[CrossRef][Medline] [Order article via Infotrieve]
  9. Jiang, C., Ting, A. T., and Seed, B. (1998) Nature 391, 82-86[CrossRef][Medline] [Order article via Infotrieve]
  10. Rossi, A., Kapahi, P., Natoli, G., Takahashi, T., Chen, Y., Karin, M., and Santoro, M. G. (2000) Nature 403, 103-108[CrossRef][Medline] [Order article via Infotrieve]
  11. Straus, D., Pascual, G., Li, M., Welch, J. S., Ricote, M., Hsiang, C.-H., Sengchanthalangsy, L. L., Ghosh, G., and Glass, C. K. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 4844-4849[Abstract/Free Full Text]
  12. Bishop-Bailey, D., and Hla, T. (1998) J. Biol. Chem. 274, 17042-17048[Abstract/Free Full Text]
  13. Kawamoto, Y., Nakamura, Y., Naito, Y., Torii, Y., Kumagai, T., Osawa, T., Ohigashi, H., Satoh, K., Imagawa, M., and Uchida, K. (2000) J. Biol. Chem. 275, 11291-11299[Abstract/Free Full Text]
  14. Kondo, M., Oya-Ito, T., Kumagai, T., Osawa, T., and Uchida, K. (2001) J. Biol. Chem. 276, 12076-12083[Abstract/Free Full Text]
  15. Kondo, M., Shibata, T., Kumagai, T., Osawa, T., Shibata, N., Kobayashi, M., Sasaki, S., Iwata, M., Noguchi, N., and Uchida, K. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 7367-7372[Abstract/Free Full Text]
  16. Cernuda-Morollon, E., Pineda-Molina, E., Canada, F. J., and Perez-Sala, D. (2001) J. Biol. Chem. 276, 35530-35536[Abstract/Free Full Text]
  17. Laurent, T. C., Moore, E. C., and Reichard, P. (1964) J. Biol. Chem. 239, 3436-3444[Free Full Text]
  18. Holmgren, A. (1985) Annu. Rev. Biochem. 54, 237-271[CrossRef][Medline] [Order article via Infotrieve]
  19. Holmgren, A. (1989) J. Biol. Chem. 264, 13963-13966[Free Full Text]
  20. Tagaya, Y., Maeda, Y., Mitsui, A., Kondo, N., Matsui, H., Hamuro, J., Brown, N., Arai, K., Yokota, T., and Wakasugi, H. (1989) EMBO J. 8, 757-764[Abstract]
  21. Wollman, E. E., d'Auriol, L., Rimsky, L., Shaw, A., Jacquot, J.-P., Wingfield, P., Graber, P., Dessarps, F., Robin, P., Galibert, F., Bertoglio, J., and Fradelizi, D. (1988) J. Biol. Chem. 263, 15506-15512[Abstract/Free Full Text]
  22. Arner, E. S., and Holmgren, A. (2000) Eur. J. Biochem. 267, 6102-6109[Abstract/Free Full Text]
  23. Yodoi, J., and Uchiyama, T. (1992) Immunol. Today 13, 405-411[CrossRef][Medline] [Order article via Infotrieve]
  24. Nakamura, H., Nakamura, K., and Yodoi, J. (1997) Annu. Rev. Immunol. 15, 351-369[CrossRef][Medline] [Order article via Infotrieve]
  25. Holmgren A. (1995) Structure 3, 239-243[Medline] [Order article via Infotrieve]
  26. Tagaya, Y., Wakasugi, H., Masutani, H., Nakamura, H., Iwata, S., Mitsui, A., Fujii, S., Wakasugi, N., Tursz, T., and Yodoi, J. (1990) Mol. Immunol. 27, 1279-1289[Medline] [Order article via Infotrieve]
  27. Narayanan, P. K., Goodwin, E. H., and Lehnert, B. E. (1997) Cancer Res. 57, 3963-3971[Abstract]
  28. Rothe, G., and Valet, G. (1990) J. Leukocyte Biol. 47, 440-448[Abstract]
  29. Laemmli, U. K. (1970) Nature 227, 680-685[Medline] [Order article via Infotrieve]
  30. Ellman, G. L. (1959) Arch. Biochem. Biophys. 82, 70-77[Medline] [Order article via Infotrieve]
  31. Riddles, P. W., Blakeley, R. L., and Zerner, B. (1983) Methods Enzymol. 91, 49-60[Medline] [Order article via Infotrieve]
  32. Chinery, R., Coffey, R. J., Graves-Deal, R., Kirkland, S. C., Sanchez, S. C., Zackert, W. E., Oates, J. A., and Morrow, J. D. (1999) Cancer Res. 59, 2739-2746[Abstract/Free Full Text]
  33. Rovin, B. H., Wilmer, W. A., Lu, L., Doseff, A. I., Dixon, C., Kotur, M., and Hilbelink, T. (2002) Kidney Int. 61, 1293-1302[CrossRef][Medline] [Order article via Infotrieve]
  34. Shahabi, N. A., Chengini, N., and Wittliff, J. L. (1987) Exp. Cell Biol. 55, 18-27[Medline] [Order article via Infotrieve]
  35. Powis, G., Mustacich, D., and Coon, A. (2000) Free Radic. Biol. Med. 29, 312-322[CrossRef][Medline] [Order article via Infotrieve]
  36. Moos, P. J., Edes, K., Cassidy, P., Massuda, E., and Fitzpatrick, F. A. (2003) J. Biol. Chem. 278, 745-750[Abstract/Free Full Text]
  37. Fukushima, M. (1990) Eicosanoids 3, 189-199[Medline] [Order article via Infotrieve]
  38. Herschman, H. R., Reddy, S. T., and Xie, W. (1997) Adv. Exp. Med. Biol. 407, 61-66[Medline] [Order article via Infotrieve]
  39. Offenbacher, S., Odle, B. M., and Van Dyke, T. E. (1986) J. Periodontal Res. 21, 101-112[Medline] [Order article via Infotrieve]
  40. Gilroy, D. W., Colville-Nash, P. R., Willis, D., Chivers, J., Paul-Clark, M. J., and Willoughby, D. A. (1999) Nat. Med. 5, 698-701[CrossRef][Medline] [Order article via Infotrieve]
  41. McGeer, P. L., McGeer, E. G., Rogers, J., and Sibley, J. (1990) Lancet 335, 1037[Medline] [Order article via Infotrieve]
  42. Lucca, U., Tettamanti, M., Forloni, G., and Spagnoli, A. (1994) Biol. Psychiatry 36, 854-856[CrossRef][Medline] [Order article via Infotrieve]
  43. Rogers, J., Kirby, L. C., Hempelman, S. R., Berry, D. L., McGeer, P. L., Kaszniak, A. W., Zalinski, J., Cofield, M., Mansukhani, L., and Willson, P. (1993) Neurology 43, 1609-1611[Abstract]
  44. Breitner, J. C. S., Gau, B. A., Welsh, K. A., Plassman, B. L., McDonald, W. M., Helmas, M. J., and Anthony, J. C. (1994) Neurology 44, 227-232[Abstract]
  45. Broe, G. A., Henderson, A. S., Creasey, H., McCusker, E., Korten, H. E., Jorm, A. F., Longley, W., and Anthony, J. C. (1990) Neurology 40, 1698-1707[Abstract]
  46. Graves, A. B., White, E., Koepsell, T. D., Reifler, B. V., Van Belle, G., Larson, E. B., and Raskind, M. (1990) Ann. Neurol. 28, 766-774[Medline] [Order article via Infotrieve]
  47. Jenkinson, M. I., Bliss, M. R., Brain, A. T., and Scott, D. L. (1989) Br. J. Rheumatol. 28, 86-87
  48. Li, G., Shen, Y. C., Chen, C. H., Zhau, Y. W., and Silverman, J. M. (1992) Neurology 42, 1481-1482[Abstract]
  49. Myllykangas-Luosujarvi, R., and Isomaki, H. (1994) Br. J. Rheumatol. 33, 501-502[Medline] [Order article via Infotrieve]
  50. Rich, J. B., Rasmusson, D. X., Folstein, M. F., Carson, K. A., Kawas, C., and Brandt, J. (1995) Neurology 45, 51-55[Abstract]
  51. Bui, T., and Straus, D. S. (1998) Biochim. Biophys. Acta 1397, 31-42[Medline] [Order article via Infotrieve]
  52. Fukushima, M. (1992) Prostaglandins Leukot. Essent. Fatty Acids 47, 1-12[Medline] [Order article via Infotrieve]
  53. Powis, G., and Montfort, W. R. (2001) Ann. Rev. Phamacol. Toxicol. 41, 261-295[CrossRef][Medline] [Order article via Infotrieve]
  54. Baker, A., Payne, C. M., Briehl, M. M., and Powis, G. (1997) Cancer Res. 57, 5162-5167[Abstract]
  55. Andoh, T., Chock, P. B., and Chiueh, C. C. (2002) J. Biol. Chem. 277, 9655-9669[Abstract/Free Full Text]
  56. Narumiya, S., Ohno, K., Fukushima, M., and Fujiwara, M. (1987) J. Pharmacol. Exp. Therap. 242, 306-311[Abstract]
  57. Khan, S. H., and Sorof, S. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 9401-9405[Abstract]
  58. Castrillo, A., Diaz-Guerra, M. J., Hortelano, S., Martin-Sanz, P., and Bosca, L. (2000) Mol. Cell. Biol. 20, 1692-1698[Abstract/Free Full Text]
  59. Olivia, J. L., Perez-Sala, D., Castrillo, A., Martinez, N., Canada, F. J., Bosca, L., and Rojas, J. M. (2003) Proc. Natl. Acad. Sci. U. S. A. 100, 4772-4777[Abstract/Free Full Text]
  60. Eklund, H., Gleason, F. K., and Holmgren, A. (1991) Proteins 11, 13-28[Medline] [Order article via Infotrieve]
  61. Li, H., Hanson, C., Fuchs, J. A., Woodward, C., and Thomas, G. J., Jr. (1993) Biochemistry 32, 5800-5808[Medline] [Order article via Infotrieve]
  62. Erve, J. C., Barofsky, E., Barofsky D. F., Deinzer, M. L., and Reed, D. J. (1995) Chem. Res. Toxicol. 8, 934-941[Medline] [Order article via Infotrieve]
  63. Haendeler, J., Hoffmann, J., Verena Tischler, V., Berk, B. C., Zeiher, A. M., and Dimmeler, S. (2002) Nat. Cell Biol. 4, 743-749[CrossRef][Medline] [Order article via Infotrieve]
  64. Stamler, J. S., Toone, E. J., Lipton, S. A., and Sucher, N. J. (1997) Neuron 18, 691-696[Medline] [Order article via Infotrieve]
  65. Stamler J. S., and Hausladen, A. (1998) Nat. Struct. Biol. 5, 247-249[Medline] [Order article via Infotrieve]